CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside

Shares of Compass Therapeutics (CMPX) plunged about 32% on Tuesday, clocking their worst day since April, after the U.S. Food and Drug Administration (FDA) said the company should run a new survival study before filing for approval of its lead cancer drug, prompting two Wall Street downgrades.CMPX…